535 results on '"Bastholt, Lars"'
Search Results
2. Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study
3. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma
4. Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients
5. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
6. Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies
7. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023
8. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023
9. Health care and socioeconomic costs for long-term survivors after implementation of checkpoint-inhibitors and targeted agents for metastatic melanoma
10. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023
11. The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma
12. ASO Visual Abstract: Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma—A National Cohort Study of 1480 Patients
13. Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial
14. Immunotherapy in Patients with mCRC
15. Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
16. Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
17. The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients
18. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
19. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
20. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
21. Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021
22. Tertiary lymphoid structures improve immunotherapy and survival in melanoma
23. Immunotherapy in Patients with mCRC
24. The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial
25. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
26. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials
27. Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
28. Supplementary Tables 1-2 from Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
29. Data from Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
30. Supplementary Figure Legend 1 from Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
31. Supplementary Figure 1 from Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
32. Health Care and Socio-Economic Costs for Long-Term Survivors after Implementation of Checkpoint-Inhibitors and Targeted Agents for Metastatic Melanoma
33. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
34. Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
35. Seasonal variation in effect of anti‐ PD ‐1 initiation on overall survival among patients with advanced melanoma
36. The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients
37. Completeness and validity in a national clinical thyroid cancer database: DATHYRCA
38. Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma
39. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
40. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
41. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
42. The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study
43. Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO Metabolites
44. Danish translation, cultural adaption and initial psychometric evaluation of the patient feedback form
45. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
46. Papillary thyroid carcinoma in Denmark 1996–2008: An investigation of changes in incidence
47. Additional file 1 of Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial
48. EMRseq : Registry-based outcome analysis on 1,000 patients with BRAF V600–mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition
49. Loss of E-cadherin as Part of a Migratory Phenotype in Melanoma Is Associated With Ulceration
50. Seasonal variation in effect of anti‐PD‐1 initiation on overall survival among patients with advanced melanoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.